New research suggests THC’s cognitive drawbacks may be mitigated when combined with a targeted anti-inflammatory drug. Cannabis research has highlighted a scientific paradox. Its best-known ...
The retrospective analysis, published in the Journal of Clinical Medicine, supports the use of tildrakizumab, an interleukin-23 (IL-23) inhibitor that was FDA approved in 2018 for moderate-to-severe ...
Life Biosciences plans to begin human clinical trials of a cellular rejuvenation therapy in optic neuropathies after ...
CommitteeforMedicinalProductsforHumanUse(CHMP)issuesapositiveopinion following re-examination, whichwillbe reviewed bythe EuropeanCommission(EC), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results